Cargando…

Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles

Severe, protracted symptoms are associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of casirivimab and imdevimab (CAS + IMD) in persons at high risk of severe coronavirus disease 2019 (COVID-19; n = 3816), evolution o...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dateng, Xu, Meng, Hooper, Andrea T., Rofail, Diana, Mohammadi, Kusha A., Chen, Yiziying, Ali, Shazia, Norton, Thomas, Weinreich, David M., Musser, Bret J., Hamilton, Jennifer D., Geba, Gregory P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406852/
https://www.ncbi.nlm.nih.gov/pubmed/37550377
http://dx.doi.org/10.1038/s41598-023-39681-7
_version_ 1785085828164222976
author Li, Dateng
Xu, Meng
Hooper, Andrea T.
Rofail, Diana
Mohammadi, Kusha A.
Chen, Yiziying
Ali, Shazia
Norton, Thomas
Weinreich, David M.
Musser, Bret J.
Hamilton, Jennifer D.
Geba, Gregory P.
author_facet Li, Dateng
Xu, Meng
Hooper, Andrea T.
Rofail, Diana
Mohammadi, Kusha A.
Chen, Yiziying
Ali, Shazia
Norton, Thomas
Weinreich, David M.
Musser, Bret J.
Hamilton, Jennifer D.
Geba, Gregory P.
author_sort Li, Dateng
collection PubMed
description Severe, protracted symptoms are associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of casirivimab and imdevimab (CAS + IMD) in persons at high risk of severe coronavirus disease 2019 (COVID-19; n = 3816), evolution of individual symptoms was assessed for resolution patterns across risk factors, and baseline SARS-CoV-2-specific antibody responses against S1 and N domains. CAS + IMD versus placebo provided statistically significant resolution for 17/23 symptoms, with greater response linked to absence of endogenous anti–SARS-CoV-2 immunoglobulin (Ig)G, IgA, or specific neutralizing antibodies at baseline, or high baseline viral load. Resolution of five key symptoms (onset days 3–5)—dyspnea, cough, feeling feverish, fatigue, and loss of appetite—independently correlated with reduced hospitalization and death (hazard ratio range: 0.31–0.56; P < 0.001–0.043), and was more rapid in CAS + IMD-treated patients lacking robust early antibody responses. Those who seroconverted late still benefited from treatment. Thus, highly neutralizing COVID-19-specific antibodies provided by CAS + IMD treatment accelerated key symptom resolution associated with hospitalization and death in those at high risk for severe disease as well as in those lacking early, endogenous neutralizing antibody responses.
format Online
Article
Text
id pubmed-10406852
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-104068522023-08-09 Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles Li, Dateng Xu, Meng Hooper, Andrea T. Rofail, Diana Mohammadi, Kusha A. Chen, Yiziying Ali, Shazia Norton, Thomas Weinreich, David M. Musser, Bret J. Hamilton, Jennifer D. Geba, Gregory P. Sci Rep Article Severe, protracted symptoms are associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of casirivimab and imdevimab (CAS + IMD) in persons at high risk of severe coronavirus disease 2019 (COVID-19; n = 3816), evolution of individual symptoms was assessed for resolution patterns across risk factors, and baseline SARS-CoV-2-specific antibody responses against S1 and N domains. CAS + IMD versus placebo provided statistically significant resolution for 17/23 symptoms, with greater response linked to absence of endogenous anti–SARS-CoV-2 immunoglobulin (Ig)G, IgA, or specific neutralizing antibodies at baseline, or high baseline viral load. Resolution of five key symptoms (onset days 3–5)—dyspnea, cough, feeling feverish, fatigue, and loss of appetite—independently correlated with reduced hospitalization and death (hazard ratio range: 0.31–0.56; P < 0.001–0.043), and was more rapid in CAS + IMD-treated patients lacking robust early antibody responses. Those who seroconverted late still benefited from treatment. Thus, highly neutralizing COVID-19-specific antibodies provided by CAS + IMD treatment accelerated key symptom resolution associated with hospitalization and death in those at high risk for severe disease as well as in those lacking early, endogenous neutralizing antibody responses. Nature Publishing Group UK 2023-08-07 /pmc/articles/PMC10406852/ /pubmed/37550377 http://dx.doi.org/10.1038/s41598-023-39681-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Li, Dateng
Xu, Meng
Hooper, Andrea T.
Rofail, Diana
Mohammadi, Kusha A.
Chen, Yiziying
Ali, Shazia
Norton, Thomas
Weinreich, David M.
Musser, Bret J.
Hamilton, Jennifer D.
Geba, Gregory P.
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
title Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
title_full Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
title_fullStr Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
title_full_unstemmed Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
title_short Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
title_sort casirivimab + imdevimab accelerates symptom resolution linked to improved covid-19 outcomes across susceptible antibody and risk profiles
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406852/
https://www.ncbi.nlm.nih.gov/pubmed/37550377
http://dx.doi.org/10.1038/s41598-023-39681-7
work_keys_str_mv AT lidateng casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles
AT xumeng casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles
AT hooperandreat casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles
AT rofaildiana casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles
AT mohammadikushaa casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles
AT chenyiziying casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles
AT alishazia casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles
AT nortonthomas casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles
AT weinreichdavidm casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles
AT musserbretj casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles
AT hamiltonjenniferd casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles
AT gebagregoryp casirivimabimdevimabacceleratessymptomresolutionlinkedtoimprovedcovid19outcomesacrosssusceptibleantibodyandriskprofiles